Raptor Pharmaceuticals Corp. (OTC: RPTP) and TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced the completion of merger. The new entity will be called Raptor Pharmaceutical Corp. and to trade under NASDAQ Ticker "RPTP". It will be headquartered in Novato, California and managed by Raptor's existing management team.
We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering. We published a full review of this over at BioHealthInvestor.com. The list includes Biosante Pharmaceuticals, Inc. (NASDAQ: BPAX), Cell Genesys, Inc. (NASDAQ: CEGE), EPIX Pharmaceuticals, Inc. [...]
TorreyPines Therapeutics (
NASDAQ: TPTX) has announced its strategic plan for 2008. Unfortunately it doesn't look or sound very promising. The company will focus on clinical development activities to maximize the value of the company's versatile lead compounds, which are AMPA/kainate receptor antagonists tezampanel and NGX426 and muscarinic agonist NGX267. It will conduct a clinical guidance meeting with the FDA in the first half of the year to discuss the efficacy results from a recently completed Phase II trial for acute migraine headaches. It will also initiate a Phase II trial of tezampanel in muscle spasticity and rigidity secondary to spinal...
(based on closing prices 11-Oct & expected near-term catalysts)
1) EXACT Sciences (EXAS): On the verge of exponential increase in share price with likely inclusion in CRC screening guidelines in November, V2 technology trial results due before EOY07, and pending NCD app for Medicare reimbursement of PreGen-Plus
2) Javelin Pharma (JAV): Imminent approval for Dyloject in UK [...]
All News |
Breaking News |
Featured Stories